Wuxi AppTec and Alphabet are in line to exit the molecule-discovery software provider, which has set the range for its initial public offering.
Schrödinger, a US-based drug development software provider backed by corporates Wuxi AppTec and Alphabet, set the terms yesterday for an initial public offering that will raise $160m if it floats at the top of its range.
The offering is set to consist of 10 million shares issued on the Nasdaq Global Market priced between $14 and $16 a share. The company filed to raise up to $100m in the IPO last week.
Schrödinger provides software that helps researchers discover…
